ADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buy
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purch...
On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it picked up in its $10 billion purchase of obesity biotech Metsera.